NCT05980000View on ClinicalTrials.gov

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 27, 2023

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2031

Conditions
Recurrent Head and Neck CancerRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck CarcinomaMetastatic Head-and-neck Squamous-cell CarcinomaMetastatic Head and Neck CancerHNSCC
Interventions
DRUG

Ramucirumab

Ramucirumab is administered at a dose of 10 mg/kg over 60 minutes.

DRUG

Pembrolizumab

Pembrolizumab is administered at a flat dose of 200 mg over 30 minutes.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Washington University School of Medicine

OTHER